Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

Blood (2024) 143 (14): 1355–1364.

https://doi.org/10.1182/blood.2023021832

Published: 2024

Includes: Supplemental data

Journal Articles

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Steven Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Markus Niggli, Karin Fijnvandraat

Blood (2023) 142 (Supplement 1): 505.

https://doi.org/10.1182/blood-2023-177963

Published: 2023

Journal Articles

Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7

Anna Kiialainen, Steven Pipe, Karin Fijnvandraat, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Johannes Oldenburg, Maria Elisa Mancuso, Christophe Dhalluin, Michaela Lehle, Peter Collins

Blood (2023) 142 (Supplement 1): 1238.

https://doi.org/10.1182/blood-2023-173015

Published: 2023

Journal Articles

Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

Blood (2022) 140 (Supplement 1): 457–459.

https://doi.org/10.1182/blood-2022-157264

Published: 2022

Journal Articles

Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis

Kathelijn Fischer, MD PhD MSc, Pratima Chowdary, FRCPath, MRCPath, MRCP, MD, Peter Collins, MD, Amy Cotterill, PhD, Barbara Konkle, MD, Victor S. Blanchette, FRCP, FRCPC, Steven W. Pipe, MD, Martin Wolfsegger, Cstat (RSS), Werner Engl, PhD Cstat, Jimena V Goldstine, PhD, Leonard A. Valentino, MD FAAP, Gerald Spotts, PhD

Blood (2016) 128 (22): 2576.

https://doi.org/10.1182/blood.V128.22.2576.2576

Published: 2016

Journal Articles

A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss

Blood (2016) 127 (23): 2903–2914.

https://doi.org/10.1182/blood-2015-10-675629

Published: 2016

Includes: Supplemental data

Journal Articles

A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders

Ilenia Simeoni, Jonathan C. Stephens, Fengyuan Hu, Sri V. V. Deevi, Karyn Megy, Tadbir K. Bariana, Claire Lentaigne, Sol Schulman, Suthesh Sivapalaratnam, Minka J. A. Vries, Sarah K. Westbury, Daniel Greene, Sofia Papadia, Marie-Christine Alessi, Antony P. Attwood, Matthias Ballmaier, Gareth Baynam, Emilse Bermejo, Marta Bertoli, Paul F. Bray, Loredana Bury, Marco Cattaneo, Peter Collins, Louise C. Daugherty, Rémi Favier, Deborah L. French, Bruce Furie, Michael Gattens, Manuela Germeshausen, Cedric Ghevaert, Anne C. Goodeve, Jose A. Guerrero, Daniel J. Hampshire, Daniel P. Hart, Johan W. M. Heemskerk, Yvonne M. C. Henskens, Marian Hill, Nancy Hogg, Jennifer D. Jolley, Walter H. Kahr, Anne M. Kelly, Ron Kerr, Myrto Kostadima, Shinji Kunishima, Michele P. Lambert, Ri Liesner, José A. López, Rutendo P. Mapeta, Mary Mathias, Carolyn M. Millar, Amit Nathwani, Marguerite Neerman-Arbez, Alan T. Nurden, Paquita Nurden, Maha Othman, Kathelijne Peerlinck, David J. Perry, Pawan Poudel, Pieter Reitsma, Matthew T. Rondina, Peter A. Smethurst, William Stevenson, Artur Szkotak, Salih Tuna, Christel van Geet, Deborah Whitehorn, David A. Wilcox, Bin Zhang, Shoshana Revel-Vilk, Paolo Gresele, Daniel B. Bellissimo, Christopher J. Penkett, Michael A. Laffan, Andrew D. Mumford, Augusto Rendon, Keith Gomez, Kathleen Freson, Willem H. Ouwehand, Ernest Turro

Blood (2016) 127 (23): 2791–2803.

https://doi.org/10.1182/blood-2015-12-688267

Published: 2016

Includes: Supplemental data

Journal Articles

Human-Cl Rhfviii Effectively and Safely Prevents Bleeding Episodes in Previously Treated Adult Patients with Severe Haemophilia A

Sigurd Knaub, PhD, Toshko Lissitchkov, MD, PhD, Kingsley Hampton, Mario Von Depka, Savita Rangarajan, MBBS, FRCP, FRCPath, Charles R.M. Hay, MD, FRCP, FRCPath, Edward GD Tuddenham, MBBS, FRCP, FRCPath, PhD, Peter Collins, MD, Katharina Holstein, MD, Angela Huth-Kühne, Ingrid Pabinger, MD, Johannes Oldenburg, MD, Johann Bichler

Blood (2012) 120 (21): 1132.

https://doi.org/10.1182/blood.V120.21.1132.1132

Published: 2012

Journal Articles

Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)

Peter Collins, Francesco Baudo, Paul Knoebl, Hervé Lévesque, László Nemes, Fabio Pellegrini, Pascual Marco, Lilian Tengborn, Angela Huth-Kühne

Blood (2012) 120 (1): 47–55.

https://doi.org/10.1182/blood-2012-02-409185

Published: 2012

Includes: Supplemental data

Journal Articles

Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry

Francesco Baudo, Peter Collins, Angela Huth-Kühne, Hervé Lévesque, Pascual Marco, László Nemes, Fabio Pellegrini, Lilian Tengborn, Paul Knoebl

Blood (2012) 120 (1): 39–46.

https://doi.org/10.1182/blood-2012-02-408930

Published: 2012

Includes: Supplemental data

Journal Articles

Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis

Uri Martinowitz, MD, Amy D. Shapiro, MD, Doris V. Quon, MD, PhD, Miguel Antonio Escobar, MD, Christine L Kempton, MD, MSc, Peter Collins, MD, Pratima Chowdary, MD, Michael Makris, MD, Pier Mannuccio Mannucci, MD, Massimo Morfini, MD, Leonard A. Valentino, MD, Edward D. Gomperts, MD, Martin Lee, PhD

Blood (2011) 118 (21): 2267.

https://doi.org/10.1182/blood.V118.21.2267.2267

Published: 2011

Journal Articles

Population Pharmacokinetic Model of ADVATE in Pediatric and Adult Patients with Hemophilia A.

Myungshin Oh, PhD, Sven Björkman, PhD, Phillip Schroth, Sandor Fritsch, PhD, Peter Collins, MD, Kathelijn Fischer, MD, PhD, MSc, Victor S. Blanchette, MD, Kathleen M. Casey, PhD, Gerald Spotts, PhD, Bruce M. Ewenstein, MD, PhD

Blood (2009) 114 (22): 3492.

https://doi.org/10.1182/blood.V114.22.3492.3492

Published: 2009

Journal Articles

Rituximab for Treatment of Resistant Inhibitors in Severe Haemophilia a: A Consecutive National Cohort.

Raina Liesner, MA, MBBChir, MD, MRCP, MRCPCH.F, Mary Mathias, BA, MBBS, MRCP, FRCPath, John Hanley, Russell Keenan, PhD, David M. Keeling, MD, Michael Laffan, Elizabeth Chalmers, Charles R.M. Hay, MD, FRCP, FRCPath, Rhona Maclean, Savita Rangarajan, MBBS, FRCP, FRCPath, Mike Williams, David J. Perry, MD, PhD, FRCP, FRCPath, Peter Collins

Blood (2008) 112 (11): 2275.

https://doi.org/10.1182/blood.V112.11.2275.2275

Published: 2008

Journal Articles

Efficacy and Safety of Secondary Prophylactic Versus On-Demand Sucrose-Formulated Recombinant Factor VIII Treatment in Adults with Severe Hemophilia A: Results from a 13-Month Crossover Study

Peter Collins, Albert Faradji, Massimo Morfini, Monika Maas Enriquez, MD, Eduard Gorina, MD, Lawrence Schwartz, Georg Lemm, MD, PhD

Blood (2008) 112 (11): 516.

https://doi.org/10.1182/blood.V112.11.516.516

Published: 2008

Journal Articles

Effect of Normal Variation in Factor VIII Pharmacokinetics on Prophylactic Dosing Requirements in Severe Classical Hemophilia.

Peter Collins, Kathelijn Fischer, MD, PhD, MSC, Victor S. Blanchette, FRCP, Sven Björkman, Myungshin Oh, Phillip Schroth, Kathleen M. Casey, PhD, Gerald Spotts, PhD, Sandor Fritsch, Bruce M. Ewenstein, MD, PhD

Blood (2008) 112 (11): 1222.

https://doi.org/10.1182/blood.V112.11.1222.1222

Published: 2008

Journal Articles

Internal and External Determinants of Bleeding Patterns on Prophylaxis for Severe Haemophilia A.

Kathelijn Fischer, MD, PhD, Peter Collins, MD, Jan Astermark, MD, Victor S. Blanchette, MD, Sven Bjorkman, PhD, Myungshin Oh, PhD, Phillip Schroth, Sandor Fritsch, PhD, Kathleen M. Casey, PhD, Gerald Spotts, PhD, Bruce M. Ewenstein, MD, PhD

Blood (2007) 110 (11): 1145.

https://doi.org/10.1182/blood.V110.11.1145.1145

Published: 2007

Journal Articles

Pharmacokinetics of Global Assays of Haemostasis in Severe Haemophilia A.

Peter Collins, Elizabeth Stephens, Georgia Florou, Nicola Macartney, Lee Hathaway, Alan Eldridge, Sarah Lewis

Blood (2006) 108 (11): 1620.

https://doi.org/10.1182/blood.V108.11.1620.1620

Published: 2006

Journal Articles

The European Acquired Haemophilia (EACH) Registry.

Francesco Baudo, MD, Jef Arnout, MD, Peter Collins, MD, Angela Huth-Kühne, MD, Hervé Levesque, MD, Paul Knoebl, MD, Pascual Marco, MD, Laszlo Nemes, MD, Lilian Tengborn

Blood (2005) 106 (11): 3205.

https://doi.org/10.1182/blood.V106.11.3205.3205

Published: 2005

NARROW

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7

Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis

A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss

A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders

Human-Cl Rhfviii Effectively and Safely Prevents Bleeding Episodes in Previously Treated Adult Patients with Severe Haemophilia A

Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)

Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry

Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis

Population Pharmacokinetic Model of ADVATE in Pediatric and Adult Patients with Hemophilia A.

Rituximab for Treatment of Resistant Inhibitors in Severe Haemophilia a: A Consecutive National Cohort.

Efficacy and Safety of Secondary Prophylactic Versus On-Demand Sucrose-Formulated Recombinant Factor VIII Treatment in Adults with Severe Hemophilia A: Results from a 13-Month Crossover Study

Effect of Normal Variation in Factor VIII Pharmacokinetics on Prophylactic Dosing Requirements in Severe Classical Hemophilia.

Internal and External Determinants of Bleeding Patterns on Prophylaxis for Severe Haemophilia A.

Pharmacokinetics of Global Assays of Haemostasis in Severe Haemophilia A.

The European Acquired Haemophilia (EACH) Registry.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only